Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LNSR 
LENSAR Inc (LNSR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: LNSR (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
2 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Year Target Price $15
Year Target Price $15
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 118.26% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 151.91M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 2 | Beta 0.52 | 52 Weeks Range 3.50 - 17.31 | Updated Date 06/30/2025 |
52 Weeks Range 3.50 - 17.31 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.86 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -99.17% | Operating Margin (TTM) -11.05% |
Management Effectiveness
Return on Assets (TTM) -6.31% | Return on Equity (TTM) -304.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 129133659 | Price to Sales(TTM) 2.66 |
Enterprise Value 129133659 | Price to Sales(TTM) 2.66 | ||
Enterprise Value to Revenue 2.26 | Enterprise Value to EBITDA -1.04 | Shares Outstanding 11905000 | Shares Floating 8495069 |
Shares Outstanding 11905000 | Shares Floating 8495069 | ||
Percent Insiders 19.64 | Percent Institutions 43.62 |
Analyst Ratings
Rating 2 | Target Price 15 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
LENSAR Inc
Company Overview
History and Background
LENSAR, Inc., founded in 2004, is a global medical technology company focused on developing and commercializing its femtosecond laser technology for refractive cataract surgery. Their flagship product is the LENSAR Laser System.
Core Business Areas
- Femtosecond Laser Systems for Cataract Surgery: Design, manufacture, and sale of femtosecond laser systems used in cataract surgery to create precise incisions and fragment the cataract lens.
Leadership and Structure
The leadership team typically consists of a CEO, CFO, and other key executives overseeing research and development, sales, and marketing. The organizational structure is typically hierarchical, with functional departments reporting to senior management.
Top Products and Market Share
Key Offerings
- LENSAR Laser System: Femtosecond laser system used for cataract surgery. Competitors include Alcon's LenSx, Johnson & Johnson Vision's Catalys, and Bausch + Lomb's Victus. Market share data is difficult to precisely pinpoint due to the competitive dynamics and proprietary information. Revenue generated directly from this product is not publicly broken out as it is the primary product line.
Market Dynamics
Industry Overview
The cataract surgery market is driven by an aging population and technological advancements in surgical procedures. It is a competitive market with several major players.
Positioning
LENSAR Inc. is positioned as a technology innovator in the femtosecond laser cataract surgery segment. They focus on precision, and improved patient outcomes.
Total Addressable Market (TAM)
The global ophthalmic surgical devices market is expected to reach billions of dollars. LENSAR's TAM is the segment of the market utilizing femtosecond laser-assisted cataract surgery (FLACS). Their positioning centers around precise lens fragmentation.
Upturn SWOT Analysis
Strengths
- Advanced femtosecond laser technology
- Precise and predictable surgical outcomes
- Focus on innovation
- Strong brand reputation (among a specific subset of surgeons)
Weaknesses
- High cost of equipment
- Limited product diversification
- Reliance on capital equipment sales
- Smaller market share compared to larger competitors
Opportunities
- Expanding applications of femtosecond laser technology
- Increasing adoption of FLACS
- Geographic expansion into emerging markets
- Partnerships with ophthalmic surgeons and institutions
Threats
- Competition from established players
- Technological advancements from competitors
- Economic downturns affecting capital equipment spending
- Regulatory changes and reimbursement pressures
Competitors and Market Share
Key Competitors
- ALC
- JNJ
- BHC
Competitive Landscape
LENSAR has the advantage of cutting-edge femtosecond laser technology, but faces disadvantages because of the competition of established brands with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends would require reviewing past financial reports. It is subject to external factors like the economy.
Future Projections: Future projections are based on analyst estimates and would be available from financial analysis platforms.
Recent Initiatives: Recent initiatives would be discussed in press releases or investor presentations.
Summary
LENSAR is a smaller player in the competitive market of femtosecond laser cataract surgery systems. Its advanced technology is a strength, but the company needs to address the competition, marketing and limited product diversification. To get the market it needs to keep up with technological innovation, expand geographically, and strategically partner within the industry. Economic conditions and regulatory changes may pose a threat.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Analyst estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on available information and estimates, and may not be precise. This is not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LENSAR Inc
Exchange NASDAQ | Headquaters Orlando, FL, United States | ||
IPO Launch date 2020-10-02 | President, CEO & Director Mr. Nicholas T. Curtis | ||
Sector Healthcare | Industry Medical Devices | Full time employees 140 | Website https://www.lensar.com |
Full time employees 140 | Website https://www.lensar.com | ||
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.